Perspectivep. 286-287

DNA Construction Limitations: Challenges and Insights

Author(s): Robert Atkinson

DOI: 10.37532/ ACTVR.2024.14(6).286-287

• Full-Text
• PDF

Perspectivep. 288-289

Drug Restructuring Limitations: Challenges in Pharmaceutical Development

Author(s): Linkin Meilne

DOI: 10.37532/ACTVR.2024.14(6).288-289

• Full-Text
• PDF

Perspectivep. .290-291

Excipients Limitations: Challenges in Drug Formulation and Delivery

Author(s): Tom Latham

DOI: 10.37532/ACTVR.2024.14(6).290-291

• Full-Text
• PDF

Perspectivep. 292-293

Immune Strength Enhancers Development: A Detailed Perspective

Author(s): Kutan Chimein

DOI: 10.37532/ACTVR.2024.14(6).292-293

• Full-Text
• PDF

Perspectivep. 296-297

Pharmacological Limitations on Drugs: Challenges and Implications

Author(s): Dema Lamao

DOI: 10.37532/ACTVR.2024.14(6).296-297

• Full-Text
• PDF

Perspectivep. 294-295

Pharmaceutical Limitations for Drugs: Challenges in Development and Distribution

Author(s): Mathiran Selva

DOI: 10.37532/ACTVR.2024.14(6).294-295

• Full-Text
• PDF

Perspectivep. 298-299

Quality Assurance (QA) for Vaccines: A Critical Pillar of Public Health Safety

Author(s): Raj Kiran Kulhaadi

DOI: 10.37532/ACTVR.2024.14(6).298-299

• Full-Text
• PDF

Perspectivep. 300-301

Quality Control in Gene Therapy: A Critical Framework for Success

Author(s): Regaar Noveli

DOI: 10.37532/ACTVR.2024.14(6).300-301

• Full-Text
• PDF

Perspectivep. 302-303

Quality Control in Vaccine Development: Ensuring Safety and Efficacy

Author(s): Rastum Raoki

DOI: 10.37532/ACTVR.2024.14(6).302-303

• Full-Text
• PDF

Perspectivep. 304-305

Research Involved in R&D for Gene Therapy

Author(s): Cesqurie Albeckin

DOI: 10.37532/ACTVR.2024.14(6).304-305

• Full-Text
• PDF